Contact

QIMR Berghofer Medical Research Institute Selects JPT’s GxP PepMix™ Peptide Pool Technology to Support its Phase I/II Clinical Trials of Adoptive Immunotherapy for Human Cytomegalovirus-associated Diseases

Press Release (2014)

Product(s) used in this publication:  GxP Peptides & Pools

Abstract:
Sorry, currently there is no abstract available.

Stay in touch and be the first to receive the latest news!